PDF(Pubmed)
Abstract：
BACKGROUND: Antibiotic resistance among pathogenic bacteria has created a global emergency, prompting the hunt for an alternative cure. Bacteriophages were discovered over a century ago and have proven to be a successful replacement during antibiotic treatment failure. This review discusses on the scientific investigation of phage therapy for Gram-positive pathogens and general outlook of phage therapy clinical trials and commercialization.
UNASSIGNED: This review aimed to highlight the phage therapy in Gram-positive bacteria and the need for phage therapy in the future. Phage therapy to treat Gram-positive bacterial infections is in use for a very long time. However, limited review on the phage efficacy in Gram-positive bacteria exists. The natural efficiency and potency of bacteriophages against bacterial strains have been advantageous amidst the other non-antibiotic agents. The use of phages to treat oral biofilm, skin infection, and recurrent infections caused by Gram-positive bacteria has emerged as a predominant research area in recent years. In addition, the upsurge in research in the area of phage therapy for spore-forming Gram-positive bacteria has added a wealth of information to phage therapy.
CONCLUSIONS: We conclude that the need of phage as an alternative treatment is obvious in future. However, phage therapy can be used as reserve treatment. This review focuses on the potential use of phage therapy in treating Gram-positive bacterial infections, as well as their therapeutic aspects. Furthermore, we discussed the difficulties in commercializing phage drugs and their problems as a breakthrough medicine.
UNASSIGNED: This review aimed to highlight the phage therapy in Gram-positive bacteria and the need for phage therapy in the future. Phage therapy to treat Gram-positive bacterial infections is in use for a very long time. However, limited review on the phage efficacy in Gram-positive bacteria exists. The natural efficiency and potency of bacteriophages against bacterial strains have been advantageous amidst the other non-antibiotic agents. The use of phages to treat oral biofilm, skin infection, and recurrent infections caused by Gram-positive bacteria has emerged as a predominant research area in recent years. In addition, the upsurge in research in the area of phage therapy for spore-forming Gram-positive bacteria has added a wealth of information to phage therapy.
CONCLUSIONS: We conclude that the need of phage as an alternative treatment is obvious in future. However, phage therapy can be used as reserve treatment. This review focuses on the potential use of phage therapy in treating Gram-positive bacterial infections, as well as their therapeutic aspects. Furthermore, we discussed the difficulties in commercializing phage drugs and their problems as a breakthrough medicine.
摘要：
背景：病原菌中的抗生素耐药性已引起全球紧急情况，促使人们寻找另一种治疗方法。噬菌体是一个多世纪前发现的，并已被证明是抗生素治疗失败期间的成功替代品。本文综述了噬菌体治疗革兰氏阳性病原体的科学研究以及噬菌体治疗临床试验和商业化的总体前景。
■这篇综述旨在强调革兰氏阳性细菌中的噬菌体疗法以及将来对噬菌体疗法的需求。用于治疗革兰氏阳性细菌感染的噬菌体疗法使用了很长时间。然而,对革兰氏阳性细菌中噬菌体功效的评价有限。噬菌体对细菌菌株的天然效率和效力与其他非抗生素试剂相比是有利的。使用噬菌体治疗口腔生物膜，皮肤感染,近年来，由革兰氏阳性细菌引起的复发性感染已成为主要的研究领域。此外,噬菌体疗法领域的研究热潮为噬菌体疗法增加了大量的信息。
结论：我们得出结论，噬菌体作为替代治疗的需求在未来是显而易见的。然而,噬菌体疗法可用作储备治疗。这篇综述着重于噬菌体疗法在治疗革兰氏阳性细菌感染中的潜在用途。以及他们的治疗方面。此外，我们讨论了噬菌体药物商业化的困难及其作为突破性药物的问题。
■这篇综述旨在强调革兰氏阳性细菌中的噬菌体疗法以及将来对噬菌体疗法的需求。用于治疗革兰氏阳性细菌感染的噬菌体疗法使用了很长时间。然而,对革兰氏阳性细菌中噬菌体功效的评价有限。噬菌体对细菌菌株的天然效率和效力与其他非抗生素试剂相比是有利的。使用噬菌体治疗口腔生物膜，皮肤感染,近年来，由革兰氏阳性细菌引起的复发性感染已成为主要的研究领域。此外,噬菌体疗法领域的研究热潮为噬菌体疗法增加了大量的信息。
结论：我们得出结论，噬菌体作为替代治疗的需求在未来是显而易见的。然而,噬菌体疗法可用作储备治疗。这篇综述着重于噬菌体疗法在治疗革兰氏阳性细菌感染中的潜在用途。以及他们的治疗方面。此外，我们讨论了噬菌体药物商业化的困难及其作为突破性药物的问题。
